BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18775469)

  • 41. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
    Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
    Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
    Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
    J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
    Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Poirier D
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phytoestrogens as inhibitors of fungal 17beta-hydroxysteroid dehydrogenase.
    Kristan K; Krajnc K; Konc J; Gobec S; Stojan J; Lanisnik Rizner T
    Steroids; 2005 Aug; 70(9):626-35. PubMed ID: 15927220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
    Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
    Poirier D
    Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
    Wood J; Bagi CM; Akuche C; Bacchiocchi A; Baryza J; Blue ML; Brennan C; Campbell AM; Choi S; Cook JH; Conrad P; Dixon BR; Ehrlich PP; Gane T; Gunn D; Joe T; Johnson JS; Jordan J; Kramss R; Liu P; Levy J; Lowe DB; McAlexander I; Natero R; Redman AM; Scott WJ; Town C; Wang M; Wang Y; Zhang Z
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4965-8. PubMed ID: 16806919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling Reactions.
    Bérubé M; Poirier D
    Org Lett; 2004 Sep; 6(18):3127-30. PubMed ID: 15330604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
    Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
    FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
    Cortés-Benítez F; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.